Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AngioDynamics ( (ANGO) ) has provided an update.
On May 28, 2025, AngioDynamics, Inc. entered into a new Credit Agreement with JPMorgan Chase Bank, N.A., securing a $25 million revolving credit facility. This agreement is intended to provide financial flexibility for the company during its manufacturing transfer process, supporting its strategic growth without impacting its operations. The facility includes a maturity date of May 28, 2027, and is secured by the company’s assets, with specific financial covenants and guarantees from its subsidiary, RITA Medical Systems, LLC.
The most recent analyst rating on (ANGO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.
Spark’s Take on ANGO Stock
According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.
AngioDynamics’ overall stock score reflects significant financial challenges, including declining revenues and cash flow issues, which are partially offset by the company’s strategic focus in MedTech and promising guidance. Technical indicators suggest a neutral to slightly bearish trend, while the valuation poses risks with a negative P/E ratio. The positive earnings call and raised guidance offer some optimism, but persistent financial and operational challenges weigh on the stock’s potential.
To see Spark’s full report on ANGO stock, click here.
More about AngioDynamics
AngioDynamics, Inc. operates in the medical device industry, focusing on the development and manufacturing of minimally invasive medical devices. The company primarily offers products for vascular access, peripheral vascular disease, and oncology, targeting healthcare providers and hospitals.
Average Trading Volume: 477,519
Technical Sentiment Signal: Hold
Current Market Cap: $394.3M
For an in-depth examination of ANGO stock, go to TipRanks’ Stock Analysis page.